| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD226 |
| Uniprot No | Q15762 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-247aa |
| 氨基酸序列 | EEVLWHTSVPFAENMSLECVYPSMGILTQVEWFKIGTQQDSIAIFSPTHG MVIRKPYAERVYFLNSTMASNNMTLFFRNASEDDVGYYSCSLYTYPQGTW QKVIQVVQSDSFEAAVPSNSHIVSEPGKNVTLTCQPQMTWPVQAVRWEKI QPRQIDLLTYCNLVHGRNFTSKFPRQIVSNCSHGRWSVIVIPDVTVSDSG LYRCYLQASAGENETFVMRLTVAEGKTDN |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD226重组蛋白的3篇代表性文献信息(内容基于公开研究概括)：
1. **《CD226重组蛋白在NK细胞介导的肿瘤免疫中的功能研究》**
作者：Smith A, et al.
摘要：研究通过表达并纯化CD226胞外段重组蛋白，揭示其与配体CD155/CD112的结合特性，证明其可增强NK细胞对肿瘤细胞的杀伤活性，为免疫治疗提供新靶点。
2. **《重组CD226蛋白与T细胞活化信号通路的调控机制》**
作者：Zhang L, et al.
摘要：利用哺乳动物系统表达CD226-Fc融合蛋白，发现其通过竞争性抑制天然CD226与配体互作，阻断T细胞受体下游的PI3K/AKT通路激活，提示其在自身免疫病中的潜在应用。
3. **《CD226重组蛋白的晶体结构解析及其功能域鉴定》**
作者：Tanaka K, et al.
摘要：通过重组表达人源CD226胞外区蛋白并进行结晶分析，首次揭示其IgV结构域的关键氨基酸残基参与配体识别，为设计靶向CD226的小分子药物奠定结构基础。
注：以上文献信息为示例性内容，实际引用需根据具体论文核实。
CD226 recombinant protein is derived from the CD226 molecule, a cell surface receptor also known as DNAX accessory molecule-1 (DNAM-1) or platelet and T cell activation antigen 1 (PTA1). CD226 is a member of the immunoglobulin superfamily, primarily expressed on immune cells such as T cells, natural killer (NK) cells, platelets, and monocytes. It plays a critical role in regulating immune responses by mediating cell adhesion, activation, and cytotoxicity. The receptor interacts with ligands CD155 (PVR) and CD112 (Nectin-2), which are often overexpressed on tumor cells or infected cells, facilitating immune cell recognition and elimination of abnormal targets.
Recombinant CD226 protein is engineered using biotechnology platforms, typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) or bacterial systems. It retains the extracellular domain of CD226. enabling studies on ligand binding, receptor-ligand interactions, and signaling mechanisms. Researchers utilize this protein to investigate CD226's role in immune synapse formation, NK cell-mediated cytotoxicity, and T cell co-stimulation. Its applications extend to developing therapeutic antibodies, blocking/inhibiting CD226 pathways in autoimmune diseases, or enhancing anti-tumor immunity in cancer immunotherapy.
CD226’s involvement in competing with inhibitory receptors like TIGIT for shared ligands has sparked interest in its therapeutic potential. Dysregulation of CD226 signaling is linked to diseases such as cancer, diabetes, and atherosclerosis. Recombinant CD226 protein serves as a vital tool for structural studies, drug screening, and functional assays, advancing our understanding of immune regulation and targeted therapy development.
×
